H.C. Wainwright Thinks Arbutus Biopharma’s Stock is Going to Recover

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Arbutus Biopharma (ABUSResearch Report), with a price target of $7.50. The company’s shares closed last Thursday at $2.54, close to its 52-week low of $1.93.

According to TipRanks.com, Arce is a 4-star analyst with an average return of 9.0% and a 39.9% success rate. Arce covers the Healthcare sector, focusing on stocks such as Paratek Pharmaceuticals, Aurinia Pharmaceuticals, and Galmed Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Arbutus Biopharma with a $6.63 average price target, implying a 161.0% upside from current levels. In a report issued on July 21, JMP Securities also reiterated a Buy rating on the stock with a $9.00 price target.

See the top stocks recommended by analysts >>

The company has a one-year high of $6.50 and a one-year low of $1.93. Currently, Arbutus Biopharma has an average volume of 1.05M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company is headquartered in Burnaby, Canada.

Read More on ABUS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More